Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 28 November

Sam Kanaan
November 28, 2023

Morning Bell 27 November

Grady Wulff
November 27, 2023

Weekly Wrap 24 November

Grady Wulff
November 24, 2023

Morning Bell 24 November

Sam Kanaan
November 24, 2023

Morning Bell 23 November

Grady Wulff
November 23, 2023

Morning Bell 22 November

Grady Wulff
November 22, 2023

Morning Bell 21 November

Sam Kannan
November 21, 2023

Morning Bell 20 November

Grady Wulff
November 20, 2023

Weekly Wrap 17 November

Grady Wulff
November 17, 2023

Morning Bell 17 November

Sam Kanaan
November 17, 2023

Morning Bell 16 November

Sam Kanaan
November 16, 2023